Meta-analysis of 3 RCTs (643 patients with rosacea): minocycline 40 mg extended-release (DFD-29) increased IGA treatment success vs modified-release doxycycline (OR 2.51; 95% CI 1.80-3.49) and reduced lesion counts more, with no difference in adverse events.
Meta-analysisn = 643
Ghanem et al. Efficacy and safety of oral minocycline hydrochloride 40 mg extended-release capsules (DFD-29) versus doxycycline in rosacea: a systematic review and meta-analysis